From Wikipedia, the free encyclopedia
F-star Biotechnology Ltd. is a biotechnology company, founded in
Vienna in 2006,
[1] with a current main research site in
Cambridge, UK. The company is focused in developing
bispecific monoclonal antibodies using a modular combinatorial approach that engineers the
Fc constant region of an
immunoglobulin into a novel antigen-binding site.
[2]
[3]
See also
-
^
"F-star starts its operations" (PDF). F-Star. 12 June 2006. Retrieved 12 December 2016.
-
^
"Home". f-star.com.
-
^ Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, Ettl K, Kainer M, Weberhofer G, Wiederkum S, Himmler G, Mudde GC, Rüker F (2010).
"Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties". Protein Eng Des. 23 (4): 289–297.
doi:
10.1093/protein/gzq005.
PMID
20150180.